Close Menu

NEW YORK – Metastatic prostate tumors with a low mutational burden may still respond to immune checkpoint blockade immunotherapy when they are marked by an interferon-gamma-related immune signature and enhanced CD8 T cell density, according to new work by a team from the University of Texas MD Anderson Cancer Center.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.